SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
Valuation | |
---|---|
Market Cap ($M) | 233.63 |
Enterprise Value ($M) | 35.77 |
Book Value ($M) | 185.37 |
Book Value / Share | 3.53 |
Price / Book | 1.26 |
NCAV ($M) | 15.19 |
NCAV / Share | 0.29 |
Price / NCAV | 15.38 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.74 |
Return on Assets (ROA) | -0.40 |
Return on Equity (ROE) | -0.72 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 8.42 |
Current Ratio | 8.42 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 202.49 |
Assets | 372.67 |
Liabilities | 187.30 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Perlroth Victor | |||
13G/A | BlackRock, Inc. | 7.70 | -5.95 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
68,558 | 235,124 | 29.16 | |
48,548 | 191,735 | 25.32 | |
56,867 | 307,750 | 18.48 | |
61,290 | 198,100 | 30.94 | |
(click for more detail) |
Similar Companies | |
---|---|
JANX – Janux Therapeutics, Inc. | KALV – KalVista Pharmaceuticals, Inc. |
KLTO – Klotho Neurosciences, Inc. | KROS – Keros Therapeutics, Inc. |
KYMR – Kymera Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io